Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

  • Study evaluated the effect of oral treatment with NSI-189 in well-established 5xFAD mouse model for Alzheimer’s disease (AD)
  • Treatment with NSI-189 restored memory retention and learning abilities in AD mice, and reduced anxiety in control and AD mice

GERMANTOWN, Md., July 23, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the presentation of data at the Alzheimer’s Association International Conference in Chicago, Illinois, demonstrating that oral administration of NSI-189 in a mouse model of Alzheimer’s Disease leads to a significant amelioration and/or improvement in cognition measures and anxiety. Results are being presented in a poster titled ‘Effect of Neurogenic Compound NSI-189 on Indices of Cognition and Anxiety in a Mouse Model (5XFAD) of Alzheimer’s Disease.’

The study was carried out by Dr. Corinne Jolivalt’s laboratory at the University of California, San Diego, and involved the oral administration of NSI-189 to mice harboring gene changes that recreate symptoms of familial Alzheimer’s disease. Animals were treated starting at 15 weeks of age, when memory defects are first beginning to appear. Key findings include:

  • Treatment with NSI-189 significantly improved learning ability as well as retention as measured by a simple task (Barnes maze), and improved performance on a test of short term memory (Novel Object Recognition)
  • Treatment with NSI-189 improved motor learning of AD mice as measured by performance on a Rotarod test
  • NSI-189 treatment decreased anxiety levels in both AD mice and control mice as measured by an open field test

“Data from this preclinical study suggest that NSI-189 may be able to mitigate or reverse the cognitive impact of Alzheimer’s disease,” said Corinne Jolivalt, PhD, associate professor in the Department of Pathology at UC San Diego School of Medicine. “We look forward to continuing this line of inquiry to further evaluate the potential of NSI-189 in the treatment of this devastating disease.”

About Alzheimer’s disease

Alzheimer’s disease is a chronic, neurodegenerative disorder that causes progressive dementia as well as a decline in other aspects of cognition which can affect a person’s ability to interact socially or function at work. There are currently an estimated 50 million people living with dementia around the world, with numbers expected to triple by 2050.  The total estimated annual social and economic cost of dementia is $818 billion USD worldwide and is expected to reach a trillion in the coming years.

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The Company has two lead development candidates:

  • NSI-189, is a small molecule in clinical development for major depressive disorder and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.
  • NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI).

Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.


Kimberly Minarovich
Argot Partners (Investor Relations)